Company Name: J-Pharma Co., Ltd.
Name of Representative: President and CEO, Masuhiro Yoshitake
Securities Code: 520A Tokyo Stock Exchange Growth Market
October 19, 2026
J-Pharma Co., Ltd. (Head Office: Minato-ku, Tokyo; President and CEO: Masuhiro Yoshitake; hereinafter “J-Pharma” or the “Company”) announces that Envalith Co., Ltd. (“Envalith”) will initiate research coverage of J-Pharma.
As part of this initiative, an interview with J-Pharma’s Chief Financial Officer (CFO) Yutaka Fujimoto has also been published on Envalith’s website.
This initiative is part of J-Pharma’s efforts to expand its investor relations activities and provide institutional and individual investors in Japan and overseas with a better understanding of its business, development pipeline, and medium- to long-term growth strategy.
■ Background and Objectives
To help investors understand a drug discovery company’s business and growth potential, J-Pharma believes it is important to clearly explain the characteristics of its drug candidates, the unmet medical needs in their target indications, and its commercialization strategy, alongside progress in research and development.
Through Envalith’s research, J-Pharma aims to complement its own communications with an external research firm’s perspective on its business and growth strategy, and to support more informed dialogue with a broader range of investors in Japan and overseas.
■ About ENVALITH
ENVALITH is an independent equity research firm that provides company research reports in three languages: Japanese, English, and Chinese (Simplified and Traditional). Its reports are distributed to institutional and individual investors in Japan and overseas through global financial information platforms, domestic financial information services, and various media outlets.
■ CFO Interview and Research Reports
An interview with J-Pharma’s CFO, conducted on October 14, 2026, has been published on Envalith’s website. We invite investors to read the interview to gain a deeper understanding of J-Pharma.
CFO Interview Title: Japan/Korea Expansion and AMED Grant Selection Elevate the Global Development Value of Nanvuranlat
URL:https://envalith.com/ja/companies/520A/reports/01a13daa-78b3-7b28-bf38-292506c93095
Future research reports on J-Pharma are expected to be available on Envalith’s J-Pharma company page.
J-Pharma Company Page on Envalith’s Website: https://envalith.com/en/companies/520A
J-Pharma will continue to strengthen its investor communication efforts and engage in constructive dialogue with shareholders and investors to deepen their understanding of the Company’s medium- to long-term growth strategy.
Related Information
・ Investor Relations – J-Pharma Co., Ltd.
https://www.j-pharma.com/en/ir/
・ Pipeline
https://www.j-pharma.com/en/pipeline/
About J-Pharma Co., Ltd.
J-Pharma Co., Ltd. aims to pursue new possibilities for SLC transporters and contribute to the hope and health of people worldwide through the development of innovative new drugs that address unmet medical needs. Guided by this mission, J-Pharma focuses on LAT1 (L-type amino acid transporter 1), an SLC transporter discovered by its founder, and advances the development of new drugs to address the needs of patients with cancer and autoimmune diseases that are not adequately met by existing treatments.
For more information, please visit:
https://www.j-pharma.com/en/
Inquiries:
J-Pharma Co., Ltd.
Planning Department
TEL: +81-3-6432-4270
https://www.j-pharma.com/en/contact/